This HTML5 document contains 45 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n12http://dx.doi.org/10.1016/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q71939845
rdf:type
wikibase:Item
schema:description
wetenschappelijk artikel im Juli 1995 veröffentlichter wissenschaftlicher Artikel наукова стаття, опублікована в липні 1995 article scientifique publié en 1995 artículu científicu espublizáu en xunetu de 1995 scientific article published on 01 July 1995
p:P577
wds:Q71939845-04A53FAC-E2B9-41B1-BAFB-74C52D0A106A
wdt:P577
1995-07-01T00:00:00Z
p:P2093
wds:Q71939845-B51FBCC3-ADE1-415B-B1B8-B59747E42180 wds:Q71939845-50AEDD5B-5DE5-424D-9AE5-7CFBB339F745 wds:Q71939845-4C03E572-B24F-458D-9161-B91B161DE75D
wdt:P2093
L Lasagna O M Bakke K I Kaitin
rdfs:label
Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective
skos:prefLabel
Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective
schema:name
Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective
p:P50
wds:Q71939845-E00DBB92-35BF-4D76-8F22-BCA3B016AB68 wds:Q71939845-4F584D12-37E0-47C7-96E0-0CE4529B6304
wdt:P50
wd:Q64861858 wd:Q55436866
p:P1476
wds:Q71939845-8F2341D8-814C-4956-A8B5-44FAF31EC1DF
wdt:P1476
Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective
p:P304
wds:Q71939845-1EEB8779-5323-48D3-B8E9-9B81D251A0EA
wdt:P304
108-117
p:P31
wds:Q71939845-70EE0152-DFC4-4C36-8EE6-AB44527BC86C
wdt:P31
wd:Q13442814
p:P921
wds:Q71939845-E02AF46B-5410-46B3-9B55-173F9F0FC7EA
wdt:P921
wd:Q145
p:P698
wds:Q71939845-9BB1A034-3E2A-477B-AB55-5794E61A1239
wdtn:P698
n10:7628177
wdt:P698
7628177
p:P1433
wds:Q71939845-78453C34-86E5-4364-B860-55D2416E1E5F
wdt:P1433
wd:Q1101529
p:P433
wds:Q71939845-9EFCC930-70B1-414A-99C6-55955A5B2E19
p:P478
wds:Q71939845-FCFF7173-3040-4FAE-943A-67E10AFADF49
wdt:P433
1
wdt:P478
58
p:P356
wds:Q71939845-2C3EE0F2-19A3-488D-B1F6-F066A65F38E7
wdtn:P356
n12:0009-9236(95)90078-0
wdt:P356
10.1016/0009-9236(95)90078-0